Out Fox The $treet

Synergy Pharma continues a slow ramp of Turlance prescriptions. Significant cost controls helped cut the quarterly loss my nearly $10 million. The Express Scripts deal for 2019 places the biotech on a path to a huge sales ramp by Q2'19. Synergy Pharma ( SGYP ) has made several rallies towards $2, but the biotech stock hasn't held any gains despite improving prescription numbers for Trulance that treats IBS. The business developments during the last few months sets the stock up for a sustainable rally.  Read the full article on Seeking Alpha.  Disclosure: Long SGYP. Please review the disclaimer page for more details.   

Synergy Pharma management caused the current stock weakness by not accurately forecasting reduced cash burn levels. Trulance continues gaining market share and generating record prescription levels. The small biotech has a better financing position due to willingness for partnerships and licensing deals. All of these factors correlate to a stock that shouldn't trade at the lows. Synergy Pharma  ( SGYP ) reported  Q4 numbers  that deviated from guidance in a positive manner. The  investment thesis  in the stock is further enhanced that better transparency from management would've prevented the crash in the stock to new lows below $2 in the first place. Read the full article on Seeking Alpha.  Disclosure: Long SGYP. Please read the disclaimer page for more details. 

Synergy Pharma continues to grow extended prescription units for Trulance. Competitor drug Linzess produced a highly profitable Q4. Trulance prescription growth appears to lag the revenue estimates, especially in Q1. With financing in place and a spring ramp in prescriptions, the stock is positioned for buying any weakness related to missing revenue targets. With all of the drama surrounding executive leadership and cash burn at  Synergy Pharma  ( SGYP ), the market hasn't focused as much on the prescription data of Trulance. The stock has held close to $2 suggesting healthy investor appetite for the biotech at this level, but meeting 2018 targets could create further weakness in Synergy Pharma providing an opportunity to own the stock at lower prices. Read the full article on Seeking Alpha.  Disclosure: Long SGYP. Please review the disclaimer page for more details. 

Synergy Pharmaceuticals hits cash target to obtain additional debt financing. Management didn't clearly outline the path to achieving the target. The company now has financing to reduce the investment risk and allow for negotiating an ex-US sales deal. Synergy Pharmaceuticals  ( SGYP ) got the  financing news  long awaited and the stock is still trading at the lows. My theory is that the lack of transparency with hitting the cash target to obtain additional financing is holding back the stock and might finally provide an opportunity to own the biotech now trading slightly above $2. Read the full article on Seeking Alpha.  Disclosure: Long SGYP. Please review the disclaimer page for more details. 

Cash position suggests Synergy Pharma needs to raise more money before next $100 million loan tranche. New CEO has an opportunity to end financing risks to new investors. The company is near an inflection point in sales and costs that will reduce cash burn going forward. Synergy Pharmaceuticals  ( SGYP ) continues to wade through a volatile drug launch due to questionable internal decisions. The company botched the drug launch financing, but the  investment thesis  isn't altered with the recent replacement of the CEO. Read the full article on Seeking Alpha.  Disclosure: No position mentioned. Please review the disclaimer page for more details.